login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
PROMETHEUS BIOSCIENCES INC (RXDX) Stock News
NASDAQ:RXDX -
US74349U1088
-
Common Stock
199.92
USD
+0.18 (+0.09%)
Last: 6/15/2023, 8:23:19 PM
199.95
USD
+0.03 (+0.02%)
After Hours:
6/15/2023, 8:23:19 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
RXDX Latest News, Press Relases and Analysis
All
Press Releases
2 years ago - By: Bloomberg
- Mentions:
TSLA
MRK
Merck Raises 2023 Sales Forecast as Cancer Drug Keytruda, Gardasil Vaccine Surge
2 years ago - By: The Motley Fool
- Mentions:
EXAI
NVDA
SNY
BYM
Why Shares of Exscientia Jumped on Wednesday
2 years ago - By: Benzinga
- Mentions:
FXH
IYH
RYH
VHT
...
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
2 years ago - By: The Motley Fool
- Mentions:
VTYX
DICE
MRK
LLY
Why Shares of Ventyx Biosciences Rose Monday
2 years ago - By: Investor's Business Daily
- Mentions:
HZNP
AMGN
PFE
MRK
...
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
2 years ago - By: InvestorPlace
- Mentions:
AAPL
NVDA
MRK
MRNA
3 Innovative Growth Stocks to Buy for Next-Gen Profits
2 years ago - By: Halper Sadeh LLC
RXDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Prometheus Biosciences, Inc. Is Fair to Shareholders
2 years ago - By: Kahn Swick & Foti, LLC
PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX
2 years ago - By: InvestorPlace
- Mentions:
PFE
AZN
MRK
3 Undervalued Pharma Stocks to Buy for High Total Returns
2 years ago - By: Benzinga
- Mentions:
AMGN
SGEN
MRK
PFE
...
FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A
2 years ago - By: Investor's Business Daily
- Mentions:
AMGN
HZNP
SGEN
Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover
2 years ago - By: Halper Sadeh LLP
- Mentions:
MNTV
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTV, RXDX
2 years ago - By: Prometheus Biosciences
Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
2 years ago - By: Seeking Alpha
- Mentions:
MRK
ABBV
BMY
Abbvie, Bristol Myers competed with Merck in sale of Prometheus - report
2 years ago - By: Bloomberg
- Mentions:
MRK
ABBV
BMY
AbbVie, Bristol Myers Vied for Prometheus Before Merck Bought It
2 years ago - By: Investor's Business Daily
- Mentions:
PFE
BMY
JNJ
ABBV
...
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
2 years ago - By: Kahn Swick & Foti, LLC
PROMETHEUS BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX
2 years ago - By: Investor's Business Daily
- Mentions:
TSLA
TSM
LRCX
ISRG
...
Stock Market Rally Drifts Lower; Tesla Dives On Margins; ISRG, DHI, LVS Are Winners: Weekly Review
2 years ago - By: Bloomberg
- Mentions:
BLU
GSK
Beaten-Down Biotech Stocks Get Boost from M&A Boom, Lofty Prices
Please enable JavaScript to continue using this application.